Digital Biomarkers for Precision Neuroscience
- Neuroscience drug development has historically suffered a low success rate, in part due to a lack of diagnostic specificity
- We are entering a new era of precision medicine in psychiatry and neurology, enabled by novel digital biomarkers
- Monument Tx is a clinical-stage biotech company developing stratified therapeutics for schizophrenia and neuroinflammation, exemplifying this approach